Novo Nordisk stock price sinks nearly 18% as 2026 outlook jolts Wegovy trade
Copenhagen, Feb 4, 2026, 10:49 (CET) — Regular session.
- Shares of Novo Nordisk dropped roughly 18% following a warning from the Wegovy maker about potential sales and profit declines in 2026.
- Management highlighted intense U.S. price pressure alongside rising competition in the obesity drug market.
- Investors are focused on U.S. pricing details, the rise of copycat “compounded” drugs, and a leadership change in the U.S. unit set for Feb. 5.
Novo Nordisk A/S shares dropped roughly 18% in early Copenhagen trading Wednesday, last seen near 302.5 Danish crowns. The decline followed the drugmaker’s 2026 outlook, which hinted at a steep slowdown in its weight-loss business. (Reuters)
This slide is significant…
